These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 13626994)

  • 21. [Clinical pharmacology of the neuromuscular junction in myasthenia gravis. (Preliminary communication)].
    Jurenić D; Jusić A
    Neurologija; 1978; 26(1-4):37-9. PubMed ID: 754038
    [No Abstract]   [Full Text] [Related]  

  • 22. [A serum factor blocking neuromuscular transmission in myasthenia gravis: electrophysiological study with intracellular microelectrodes (author's transl)].
    Shibuya N
    Rinsho Shinkeigaku; 1978 Apr; 18(4):177-84. PubMed ID: 212240
    [No Abstract]   [Full Text] [Related]  

  • 23. Myasthenia gravis and atracurium. A case report.
    Macdonald AM; Keen RI; Pugh ND
    Br J Anaesth; 1984 Jun; 56(6):651-4. PubMed ID: 6326789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient.
    Murray MJ; DeBlock H; Erstad B; Gray A; Jacobi J; Jordan C; McGee W; McManus C; Meade M; Nix S; Patterson A; Sands MK; Pino R; Tescher A; Arbour R; Rochwerg B; Murray CF; Mehta S
    Crit Care Med; 2016 Nov; 44(11):2079-2103. PubMed ID: 27755068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of normal human serum and its ultrafiltrate on neuro-muscular transmission.
    Sandweg R; Kruckenberg P
    Electroencephalogr Clin Neurophysiol; 1968 Oct; 25(4):397. PubMed ID: 4176564
    [No Abstract]   [Full Text] [Related]  

  • 27. The neuromuscular junction: recent developments.
    Bowman WC
    Eur J Anaesthesiol; 1985 Mar; 2(1):59-93. PubMed ID: 2410263
    [No Abstract]   [Full Text] [Related]  

  • 28. Abnormalities in neuromuscular transmission, with special reference to myasthenia gravis.
    GROB D; HARVEY AM
    Am J Med; 1953 Nov; 15(5):695-709. PubMed ID: 13104438
    [No Abstract]   [Full Text] [Related]  

  • 29. Difference in sensitivity to vecuronium between patients with ocular and generalized myasthenia gravis.
    Itoh H; Shibata K; Nitta S
    Br J Anaesth; 2001 Dec; 87(6):885-9. PubMed ID: 11878691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia gravis. III. Lack of inhibitory action of fractionated thymus extracts.
    ZACKS SI
    Proc Soc Exp Biol Med; 1958 Dec; 99(3):574-5. PubMed ID: 13614427
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of atracurium in myasthenic patients undergoing thymectomy.
    Huang YG; Luo AL; Luo LK
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(2):102-6. PubMed ID: 2243832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies in neuromuscular function. II. Effects of nerve stimulation in normal subjects and in patients with myasthenia gravis.
    GROB D; HARVEY AM; JOHNS RJ
    Bull Johns Hopkins Hosp; 1956 Sep; 99(3):125-35. PubMed ID: 13364528
    [No Abstract]   [Full Text] [Related]  

  • 34. Anesthesia and myasthenia gravis.
    Blichfeldt-Lauridsen L; Hansen BD
    Acta Anaesthesiol Scand; 2012 Jan; 56(1):17-22. PubMed ID: 22091897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the reaction of the isolated phrenic nerve diaphragm preparation of various species to certain agents causing a neuromuscular block.
    BERGH NP
    Scand J Clin Lab Invest; 1953; 5 Suppl 7():5-29. PubMed ID: 13075957
    [No Abstract]   [Full Text] [Related]  

  • 36. Motor end plate changes in myasthenia gravis.
    CHURCHILL-DAVIDSON HC
    Am J Phys Med; 1959 Aug; 38():159-62. PubMed ID: 13810230
    [No Abstract]   [Full Text] [Related]  

  • 37. Some effects of extracts of thymus glands removed from patients with myasthenia gravis.
    WILSON A; OBRIST AR; WILSON H
    Lancet; 1953 Aug; 265(6782):368-71. PubMed ID: 13085784
    [No Abstract]   [Full Text] [Related]  

  • 38. [The action of potassium on neuromuscular transmission in myasthenia gravis].
    DESMEDT JE
    J Physiol (Paris); 1955; 47(4):655-7. PubMed ID: 13307448
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of myasthenia gravis.
    Saperstein DS; Barohn RJ
    Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-aminopyridine-a review.
    Soni N; Kam P
    Anaesth Intensive Care; 1982 May; 10(2):120-6. PubMed ID: 6285756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.